Guardant Health (NASDAQ:GH) Stock Price Down 7.5%

Guardant Health, Inc. (NASDAQ:GHGet Rating)’s stock price traded down 7.5% on Friday . The company traded as low as $54.41 and last traded at $54.48. 1,894 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 758,085 shares. The stock had previously closed at $58.89.

Analyst Ratings Changes

GH has been the topic of several research analyst reports. Credit Suisse Group initiated coverage on shares of Guardant Health in a report on Wednesday, August 24th. They set an “outperform” rating and a $80.00 target price on the stock. Morgan Stanley dropped their target price on shares of Guardant Health from $85.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 8th. Piper Sandler initiated coverage on shares of Guardant Health in a report on Thursday, June 2nd. They set an “overweight” rating and a $65.00 target price on the stock. The Goldman Sachs Group dropped their target price on shares of Guardant Health from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, August 8th. Finally, OTR Global downgraded shares of Guardant Health to a “positive” rating in a report on Monday, August 1st. Thirteen equities research analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health presently has a consensus rating of “Buy” and an average price target of $115.75.

Guardant Health Stock Down 4.8 %

The company has a debt-to-equity ratio of 3.56, a current ratio of 6.18 and a quick ratio of 5.83. The firm’s 50 day moving average is $51.54 and its two-hundred day moving average is $51.52. The firm has a market capitalization of $5.73 billion, a P/E ratio of -10.37 and a beta of 0.80.

Guardant Health (NASDAQ:GHGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($2.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.00). Guardant Health had a negative return on equity of 99.90% and a negative net margin of 135.03%. The company had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. During the same period last year, the firm earned ($0.96) earnings per share. The company’s revenue for the quarter was up 18.5% compared to the same quarter last year. Research analysts predict that Guardant Health, Inc. will post -6.12 EPS for the current year.

Insider Transactions at Guardant Health

In other news, insider Kumud Kalia sold 2,000 shares of Guardant Health stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $51.39, for a total transaction of $102,780.00. Following the completion of the sale, the insider now owns 18,530 shares of the company’s stock, valued at $952,256.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Kumud Kalia sold 2,000 shares of the business’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $51.39, for a total value of $102,780.00. Following the completion of the transaction, the insider now owns 18,530 shares of the company’s stock, valued at $952,256.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Amelia Merrill sold 4,500 shares of the business’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $53.38, for a total value of $240,210.00. Following the completion of the transaction, the senior vice president now directly owns 24,708 shares of the company’s stock, valued at approximately $1,318,913.04. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Xponance Inc. raised its stake in Guardant Health by 1.9% during the first quarter. Xponance Inc. now owns 10,319 shares of the company’s stock worth $684,000 after acquiring an additional 190 shares in the last quarter. Captrust Financial Advisors grew its holdings in shares of Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after purchasing an additional 271 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Guardant Health by 4.9% during the second quarter. Commonwealth Equity Services LLC now owns 6,120 shares of the company’s stock worth $246,000 after purchasing an additional 286 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of Guardant Health by 6.3% during the second quarter. D.A. Davidson & CO. now owns 6,144 shares of the company’s stock worth $248,000 after purchasing an additional 364 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Guardant Health by 0.9% during the second quarter. Envestnet Asset Management Inc. now owns 42,461 shares of the company’s stock worth $1,713,000 after purchasing an additional 386 shares during the last quarter. Institutional investors and hedge funds own 89.36% of the company’s stock.

About Guardant Health

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Read More

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.